Volume 122, Issue 6 pp. 1014-1023

Structure–function analysis of the extracellular domains of the Duffy antigen/receptor for chemokines: characterization of antibody and chemokine binding sites

Christophe Tournamille

Christophe Tournamille

INSERM U76, Institut National de la Transfusion Sanguine, Paris, France, and

Search for more papers by this author
Anne Filipe

Anne Filipe

INSERM U76, Institut National de la Transfusion Sanguine, Paris, France, and

Search for more papers by this author
Kazimiera Wasniowska

Kazimiera Wasniowska

Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocaw, Poland

Search for more papers by this author
Pierre Gane

Pierre Gane

INSERM U76, Institut National de la Transfusion Sanguine, Paris, France, and

Search for more papers by this author
Elwira Lisowska

Elwira Lisowska

Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocaw, Poland

Search for more papers by this author
Jean-Pierre Cartron

Jean-Pierre Cartron

INSERM U76, Institut National de la Transfusion Sanguine, Paris, France, and

Search for more papers by this author
Yves Colin

Yves Colin

INSERM U76, Institut National de la Transfusion Sanguine, Paris, France, and

Search for more papers by this author
Caroline Le Van Kim

Caroline Le Van Kim

INSERM U76, Institut National de la Transfusion Sanguine, Paris, France, and

Search for more papers by this author
First published: 03 September 2003
Citations: 44
Professor Caroline Le Van Kim, INSERM U76, INTS, 6 rue Alexandre Cabanel, 75015 Paris, France. E-mail: [email protected]

Abstract

Summary. The Duffy antigen/receptor for chemokines (DARC), a seven-transmembrane glycoprotein carrying the Duffy (Fy) blood group, acts as a widely expressed promiscuous chemokine receptor. In a structure–function study, we analysed the binding of chemokines and anti-Fy monoclonal antibodies (mAbs) to K562 cells expressing 39 mutant forms of DARC with alanine substitutions spread out on the four extracellular domains (ECDs). Using synthetic peptides, we defined previously the Fy6 epitope (22-FEDVW-26), and we characterized the Fya epitope as the linear sequence 41-YGANLE-46. In agreement with these results, mutations of F22-E23, V25 and Y41, G42, N44, L45 on ECD1 abolished the binding of anti-Fy6 and anti-Fya mAbs to K562 cells respectively, Anti-Fy3 binding was abolished by D58–D59 (ECD1), R124 (ECD2), D263 and D283 (ECD4) substitutions. Mutations of C51 (ECD1), C129 (ECD2), C195 (ECD3) and C276 (ECD4 severely reduced anti-Fy3 and CXC-chemokine ligand 8 (CXCL-8) binding. CXCL-8 binding was also abrogated by mutations of F22–E23, P50 (ECD1) and D263, R267, D283 (ECD4). These results defined the Fya epitope and suggested that (1) two disulphide bridges are involved in the creation of an active chemokine binding pocket; (2) a limited number of amino acids in ECDs 1–4 participate in CXCL-8 binding; and (3) Fy3 is a conformation-dependent epitope involving all ECDs. We also showed that N-glycosylation of DARC occurred on N16SS and did not influence antibody and chemokine binding.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.